Clinical trial NCT05579327: Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)
Official title: Withdrawal of Tiratricol Treatment in Males with Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency): a Double-blind, Randomized, Placebo-controlled Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Monocarboxylate Transporter 8 Deficiency
Allan-Herndon-Dudley Syndrome
Keywords: MCT8
MCT8 deficiency
Allan-Herndon-Dudley syndrome
Tiratricol
Triac
Lead sponsor: Rare Thyroid Therapeutics International AB
Sponsor class: INDUSTRY
Collaborators: name: Premier Research Group plc
name: Egetis Therapeutics
First posted: 2022-10-13
Enrollment: 16
Sex: MALE
Minimum age (years): 4
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Patients having demonstrated stable maintenance treatment with tiratricol will be randomized to receive placebo or tiratricol for 30 days or until reaching rescue criterion (serum total T3 \> ULN of the participant's normal range, for a sample collected during the 30-day Randomized Treatment Period). In other words, the patients will be randomized to complete withdrawal of tiratricol treatment (placebo) for 30 days or to continue with the stable tiratricol maintenance treatment for 30 days. If during the 30 days, a rescue criterion (serum total T3 \> ULN of the participant's normal range) is reached, the randomized treatment will be stopped, and the patient will go back on unblinded tiratricol treatment.

Serum total T3 concentrations measured during the Randomized Treatment Period that are below the LLN of the normal range will not lead to any modifications to the blinded study drug administration schedule of daily tiratricol dosing.
Primary purpose: TREATMENT

Brief summary: This is a double-blind, randomized phase 3 multicenter placebo-controlled study in at least 16 evaluable male participants diagnosed with MCT8 deficiency. Male participants, from 4 years of age (at randomization) and having demonstrated stable maintenance treatment with tiratricol, will be randomized to receive placebo or tiratricol for 30 days or until reaching rescue criterion (serum total triiodothyronine \[T3\] \> upper limit of normal \[ULN\] of the participant's normal range, for a sample collected during the 30-day Randomized Treatment Period). The research hypothesis to be tested is that, for participants in the placebo group, removal of tiratricol will lead to an increase of serum total T3 concentration, measured by liquid chromatography with tandem mass spectrometry (LC/MS/MS), above the ULN and requirement of rescue treatment with tiratricol, compared to those who continue to receive tiratricol.

Detailed description: The Screening Period includes a Screening Visit and a period of open-label treatment in which a stable maintenance dose of tiratricol, essential for progression into the Randomized Treatment Period, will be established. The duration of this period will vary depending on whether the participant is currently receiving treatment with tiratricol at the time of enrollment in the study (Cohort A), or if they are considered to be tiratricol treatment-naïve (Cohort B). Participants are considered to be tiratricol-naïve if they have never previously been administered tiratricol, or have previously received tiratricol but are not receiving tiratricol at the time of enrollment.

For participants in Cohort A, once eligibility is confirmed during the Screening Visit, the study starts with a Run-in Period to ensure that participants are being administered a stable dose of tiratricol, as determined by meeting the Stable Dose Criterion.

For participants in Cohort B, once eligibility is confirmed during the Screening Visit, the study starts with a Dose Titration Period to allow titration to a stable dose of tiratricol, as determined by meeting the Stable Dose Criterion.

The Stable Dose Criterion is defined as at least 4 weeks' treatment (during the period from the start of screening to randomization) at a fixed daily dose that is targeting a serum total T3, measured by LC/MS/MS, at the lower limit of normal (LLN) with at least 2 consecutive serum total T3 results that are within the study titration range: within 20% below the LLN to the 75th percentile of the normal range for serum total T3 (i.e., LLN + 0.75×\[ULN-LLN\]).

An evaluable participant is defined as a participant who completes the Randomized Treatment Period either by completing 30 days of double-blind treatment without meeting the rescue criterion or by meeting the rescue criterion.

Eligibility criteria: Inclusion Criteria:

1. Male participants diagnosed with a pathogenic mutation in the MCT8 gene, confirmed with a genetic test.
2. Serum total T3 concentration above the ULN of the age specific normal range:

   1. at the time of diagnosis (or the closest sample taken prior to first ever treatment with tiratricol) for participants who are currently treated with tiratricol
   2. in the Screening Visit sample, or most recent standard of care sample prior to screening, for participants who have never received and/or currently not receiving tiratricol.
3. Participants will be aged 4 years or older at the time of randomization. Participants entering screening who are \<4 years of age but expected to be aged 4 years at randomization should be discussed with the medical monitor.
4. Signed and dated informed consent form from the parents or legal guardian.

Exclusion Criteria:

1. Major illness or recent major surgery unrelated to MCT8 deficiency (in the principal investigator's judgement), defined as:

   * Conditions requiring repeated hospitalizations that are likely to confound ability to participate in the trial.
   * Major illness in the 3 months prior to the screening visit that is likely to confound the ability of the participant to participate fully within the trial and/or confound the assessment of serum total T3 and/or safety.
   * Major surgery within the 3 months prior to the screening visit or planned to take place during the study, including but not limited to major abdominal/thoracic/neurosurgical procedures.
   * Major/minor abdominal and/or maxillofacial surgery that may inhibit the administration and/or absorption of study drug.
2. Body weight \<10 kg at the Screening Visit.
3. Patients who are participating, or intend to participate, in other therapeutic and/or interventional clinical studies during the study period.
4. History of allergic reactions to components of tiratricol or any excipients in the investigational product (IP).
5. Participants with any contra-indication for treatment with tiratricol or any excipients in the IP.
6. Participants using other T3 analogues, levothyroxine, or propylthiouracil.

Randomization Criteria:

In addition to the eligibility criteria, participants must meet further criteria at the time of randomization to enter the Randomized Treatment Period.

1. Confirmation that the "Stable Dose Criterion" has been met.
2. Absence of any new or exacerbated medical or surgical condition that fulfils Exclusion criterion #1.
3. Confirmation that participant is at least 4 years of age at the time of randomization.

Primary outcomes:
measure: Proportion of participants who meet the rescue criterion (serum total T3 > ULN) from samples obtained during the 30-day double-blind Randomized Treatment Period
timeFrame: Baseline to Day 30
Secondary outcomes:
measure: Change in serum thyroid hormone variables from baseline (start of the Randomized Treatment Period) to the end of Randomized Treatment Period (completion or rescue)
timeFrame: Baseline to Day 30 or until rescue criterion is met
measure: Change in serum thyroid hormone variables (T3, T4, TSH, fT3, and fT4) from initiation of tiratricol administration at Screening to the last measurement prior to randomization (Cohort B only)
timeFrame: Screening Visit to the end of the Dose Titration Period (approximately 16 weeks)
measure: Change in the cardiovascular variables from extended ECG assessments from the last measurement prior to the start of the Randomized Treatment Period to the end of the Randomized Treatment Period (completion or rescue)
timeFrame: 1-2 days prior to baseline to Day 30 or until rescue criterion is met
measure: Change in the cardiovascular variables from 24-hour ambulatory blood pressure monitoring (ABPM) assessments
timeFrame: 1-2 days prior to baseline to Day 30 or until rescue criterion is met
measure: Change in the cardiovascular variables from extended heart rate assessments from the last measurement prior to the start of the Randomized Treatment Period to the end of the Randomized Treatment Period (completion or rescue)
timeFrame: 1-2 days prior to baseline to Day 30 or until rescue criterion is met
measure: Number of participants with normal/abnormal and not clinically significant/clinically significant cardiovascular variables from extended assessments
timeFrame: 1-2 days prior to baseline to Day 30 or until rescue criterion is met
measure: Serum concentrations of tiratricol
timeFrame: Screening Period, Days 1, 8, 15, 22, and 30, Follow-up Period (up to approximately 26 weeks)
measure: Change in serum sex hormone binding globulin from baseline (start of the Randomized Treatment Period) to the end of the Randomized Treatment Period (completion or rescue)
timeFrame: Baseline to Day 30 or until rescue criterion is met
measure: Time (days) from randomization to the time when the rescue criterion is met or the time of completion of Randomized Treatment Period (whichever comes first)
timeFrame: Baseline to Day 30 or until rescue criterion is met
measure: Frequency and severity of adverse events (AEs) and serious adverse events (SAEs)
timeFrame: Run-in/Dose Titration Period to end of study (up to approximately 26 weeks)
measure: Values and change from baseline in safety laboratory variables (full blood count)
timeFrame: Screening to end of study (up to approximately 26 weeks)
measure: Values and change from baseline in safety laboratory variables (serum renal and liver biomarkers)
timeFrame: Screening to end of study (up to approximately 26 weeks)
measure: Values and change from baseline in safety laboratory variables (total and low-density lipoprotein cholesterol)
timeFrame: Screening to end of study (up to approximately 26 weeks)
measure: Number of participants with abnormal findings in vital signs
timeFrame: Baseline to end of study (approximately 10 weeks)
measure: Number of participants with abnormal 24-hour ABPM findings (clinically significant and not clinically significant)
timeFrame: Screening to end of study (up to approximately 26 weeks)
measure: Change from baseline in weight
timeFrame: Baseline to end of study (approximately 10 weeks)
measure: Number of participants with abnormal 12-lead electrocardiogram (ECG) findings (clinically significant and not clinically significant)
timeFrame: Screening to end of study (up to approximately 26 weeks)
measure: Number of participants with abnormal extended electrocardiogram (ECG) findings (clinically significant and not clinically significant)
timeFrame: 1-2 days prior to baseline to Day 30 or until rescue criterion is met
measure: Change from baseline to end of study for ECG measures (PR interval, RR interval, QRS interval, QT interval, corrected QT interval [both correction methods QTcB and QTcF])
timeFrame: Baseline to end of study (approximately 10 weeks)
measure: Change from baseline to end of study for ECG measures (heart rate descriptive analysis)
timeFrame: Baseline to end of study (approximately 10 weeks)
measure: Number of participants with abnormal findings in the complete physical examination
timeFrame: Screening to end of study (up to approximately 26 weeks)
Other outcomes:
measure: Change in serum thyroid hormone variables from baseline (start of the Randomized Treatment Period) to the end of the Follow-up Period
timeFrame: Baseline to the end of the Follow-up Period (approximately 10 weeks)
measure: Change in serum thyroid hormone variables from the end of the Randomized Treatment Period to the end of the Follow-up Period
timeFrame: End of the Randomized Treatment Period (or when rescue criterion was met) to the end of the Follow-up Period (approximately 6 weeks)
measure: Number of tiratricol metabolites in serum
timeFrame: Run-in/Dose Titration Period to end of study (up to approximately 26 weeks)
measure: Structure of tiratricol metabolites in serum
timeFrame: Run-in/Dose Titration Period to end of study (up to approximately 26 weeks)
measure: Tiratricol metabolite concentrations in serum
timeFrame: Run-in/Dose Titration Period to end of study (up to approximately 26 weeks)
measure: Ratios of tiratricol metabolite to tiratricol concentrations in serum
timeFrame: Run-in/Dose Titration Period to end of study (up to approximately 26 weeks)
measure: Values of serum concentrations of tiratricol (pharmacokinetics)
timeFrame: Once during Run-in/Dose Titration Period (up to approximately 6 or 16 weeks) and at the Week 2 visit during the Follow-up Period
measure: Correlation between serum concentrations of tiratricol and serum total T3 concentrations
timeFrame: Run-in/Dose Titration Period to end of study (up to approximately 26 weeks)
measure: Correlation between adverse drug reactions (ADRs) and serum concentrations of tiratricol
timeFrame: Run-in/Dose Titration Period to end of study (up to approximately 26 weeks)
Locations:
city: Kissimmee
country: United States
facility: Rare Disease Research, LLC
state: Florida
city: Atlanta
country: United States
facility: Rare Disease Research, LLC
state: Georgia
city: Saint Louis
country: United States
facility: SSM Health Cardinal Glennon Children's Hospital
state: Missouri
city: Hillsborough
country: United States
facility: Rare Disease Research, LLC
state: North Carolina
city: Philadelphia
country: United States
facility: Children's Hospital of Philadelphia
state: Pennsylvania
city: Webster
country: United States
facility: Tranquil Clinical and Research Consulting Services
state: Texas
city: Rotterdam
country: Netherlands
facility: Erasmus MC
city: Cambridge
country: United Kingdom
facility: Addenbrooke's Hospital
Study officials:
affiliation: Children's Hospital of Philadelphia
name: Andrew J. Bauer, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Erasmus Medical Center
name: W. E. Visser, MD
role: PRINCIPAL_INVESTIGATOR
References: